WP7 – VACCINE RESEARCH AND DEVELOPMENT

This WP follows these objectives:

Main objective

Define tools and methods for priority-setting and identify mechanisms to increase collaboration and cooperation in vaccine and vaccination research and research funding programmes among MS

Specific objectives
  • Identify a small number of vaccines based on unmet needs for specific age categories to be used as examples to develop such a framework (e.g. a pediatric, an adolescent and an adult/elderly vaccine)
  • Map existing priority setting tools used for research and develop priority-setting, and develop a specific priority-setting framework for vaccine and vaccination research
  • Identify sustainable mechanisms to decrease funding fragmentation and increase the potential for shared funding on common priorities

EU-JAV is implementing a process leading to evidence-based and transparent definition of research priorities in Europe in the field of vaccination research, focusing initially on four “pilot” pre-selected vaccines (pertussis, measles-containing combination vaccines, influenza and HPV), then expanding to all vaccines used in the EU for which research might provide insights on how to maximize coverage, including against COVID-19. Another objective of the Joint Action is to identify sustainable mechanisms to decrease funding fragmentation and increase the potential more collaboration and shared funding on common priorities. The work will be finalized in March 2022.

Annual Lists on Research Priorities on Vaccination

Potential mechanisms to increase collaboration in vaccine and vaccination research and cooperation for funding these programmes among Member States

The Annual Lists on Research Priorities on Vaccination

In this part of the project, the team has created two annual lists of research priorities on vaccination, extending from pilot vaccines to cover most vaccines used in the EU, and for which research might provide insights on how to maximize coverage

Project activity leaders

Marie-Paule Kieny

Inserm

Jean-Daniel Lelièvre

Inserm

Karianne Johansen

Norwegian Institute of Public Health (FHI)